China Biologic Products, Inc. through its indirect majority-owned subsidiary, Shandong Taibang, and equity investments in Xi'an Huitian and Chongqing Dalin, is currently the largest non-state-owned plasma-based biopharmaceutical company approved by the Chinese government. The company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. Blood products are biological products used in biological active preparation to collect healthy blood for raw materials, which are manufactured through biological processes or separation and purification technologies. Blood products are irreplaceable in the application of medical emergencies, and prevention & treatment for various diseases.

Contact Information

No. 14 East Hushan Road
Tai’an City, Shandong 271000
People’s Republic of China,

tel: (+86) 538-620-2306


Investor Relations

Vice President of Finance and Investor Relation
Mr. Ming Yin
tel: 86-851-360-5846
fax: 86-851-360-5555
e-mail: yinming@chinabiologic.com


Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $282M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.